Ekf Diagnostics Share Discussion Threads

[tongosti] 02/5/2021 18:01

Honestly it's mind boggling the ignorance of most. Never mind that the share price never topped the 80p for months after I warned folks. It also doesn't matter to them that 2022 forecast revenue (£47m according to sharescope) are about 20% lower than what the market are expecting this fiscal year. Any wonder the director sold and the share price had stalled for ages?Wan - are you posting tomorrow or you will skip it due to bank holiday? Ta.

[sharw] 01/5/2021 14:31

The sale of shares by a director caused me to look him up on the Investors section of the EKF website. Here is what it says:

Adam Reynolds, Non-Executive Director

Adam is a former stockbroker specialising in corporate finance. He has built, rescued and re-financed a number of public companies. He is currently Chairman of Autoclenz Group Limited, Orogen Gold plc, and Hubco Investments plc and a Director of OptiBiotix Health plc, Premaitha Health plc, and Verdes Management plc.

Hubco Investments changed its name to Big Sofa Technologies Group plc in 2016 and he resigned from the board in June 2018.

Orogen Gold became a cash shell and Sosandar PLC reversed into it in 2017 at which point he ceased to be Chairman but remained on the Board.

Verdes Management changed name to React in 2015 and he resigned at that time.

Premaitha Health changed name to Yourgene Health in 2018.

OptiBiotix Health resigned 2017

I find it somewhat disturbing that the website is so appallingly maintained. What else on it can we believe?

[jsredbird] 01/5/2021 12:10

Exactly. He is just a troll. That is what it boils down to. He doesn’t deserve any response except for being called out as a troll. Tong the troll. Call it what it is.

[masurenguy] 01/5/2021 10:12

I see that the troll has returned. Why do some posters here continue to feed him. You are just giving him the attention that he desperately craves and also prompting him to wreck this thread with his nonsense. Either just ignore or filter him !

[abeygale] 01/5/2021 09:59

(FAB) Fusion Antibodies is making antibodies for COVID vaccine companies. The stock is tightly held, and valued at 43m. It is fully funded by grants. Do your own research, and I am sure you will all be very impressed.

[hastings] 01/5/2021 09:58

Personally not concerned with the sale.I've had plenty of situations where Directors have sold sizeable chunks but the shares have gone on to perform strongly. FDEV, SDI, G4M as examples. In the case of those three, all Directors retained very large holdings as does Chris Mills here.

[donald pond] 01/5/2021 09:37

I've no position here any more so have no skin in the game. Directors can sell for lots of reasons but only buy for one. Look at SLP, lots of director sells there 2/3 years ago at 16p. Put me off buying. 120 nowDirector sells are never good, but they aren't necessarily bad. Buys are always good

[tongosti] 01/5/2021 09:30

Wan - any idea why a company executive has cashed in £350k or is this completely irrelevant? Ta.

[chris16041] 01/5/2021 09:19

you provide a fascinating case study in self delusion are you on any other boards other than this and sfor
toodle pip old chum

[tongosti] 01/5/2021 09:14

Glad you have enjoyed my riding short there from 510 to 400. I see you're following me across these boards - I wonder why. Lol.

[chris16041] 01/5/2021 09:01

Welcome back Mr Market where have you been
I am sure we will receive some words of wisdom from you in the next few weeks
Don't forget your followers on the sfor thread I am sure they are looking forward to hearing from you
Toodle pip old chap

[tongosti] 01/5/2021 08:41

Another confused individual. I warned of a top at 80p last Nov and we're still below that. Yet, I hear bizarre views that I have missed the boat. What boat?! Am my credibility. Really?!No pal - I am not looking to engage either with someone who lives in a fantasy world and is not keen to take a good look at reality. Good luck with your "investing".

[charlieej] 01/5/2021 06:57

No Tongosti, you don’t get to scurry off when the price goes against your predictions and then pop back in to snipe like nothing happened. That blows your credibility. You momentum trade and EKF got news you didn’t expect but many holders were not at all surprised about. Should you have come on and shown some humility at the time the a bit of chat about director sales now would seem reasonable. To just come in like nothing has happened when you missed the boat shows you for the child you are.

As Wan points out Adam Reynolds has been selling down for a while now. If like I have you held ekf from 25p and have kept all your Renalytix you will have Verici from that too and Trellus about to list. I expect this to continue but to give an example of how staying long has benefitted holders rather than trading if one held 1000 shares at 25p for a value of £250 Before Renalytix would spun out you would now have

1000 EKF valued at £730

45 RENX valued at £459

45 VRCI valued at £29.7

61 Trellus which are yet to be valued

So a £250 investment is now £1,218.7 without adding Trellus which given past spin off performance I would suggest holders can have a quiet confidence on. I certainly do.

I won’t engage with any response to this but looking at it explain how you or your mate mr market values the relationship with Mt Sinai here or possibly do you think mr market hasn’t fully grasped that aspect of the business?? And how, looking at the returns longer holders have had do you think you can lecture this board on the value of this business?

[wan] 01/5/2021 06:02

Quite often, Director share purchases and sales are more about timing and demand, than the underlying business or its future prospects etc.

To perhaps highlight this fact, the following transactions by Adam Reynolds appears to demonstrate that director selling does not always align with poor business prospects, and neither was it useful as an indicator/predictor of poor share price performance -

09 November 2018, Adam Reynolds, Non-executive Director, sold 1,250,000 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares")at a price of 27.25 pence per share


28 May 2019, Adam Reynolds, Non-executive Director, sold 400,000 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") at a price a 33 pence per share


One might even conclude that the same positive theme, in terms of share price performance, could apply to yesterdays transaction, time will tell!

[jsredbird] 01/5/2021 00:30

Oh, you are so smart. And a troll.

[tongosti] 30/4/2021 22:58

A senior director cashing in £350k wouldn't have done so unless he thought shares are not as cheap as Joes of the world would want you to believe, would he?Think about it pal. Just try... :)

[jsredbird] 30/4/2021 18:13

And cue the music: “the troll cane back, he couldn’t stay away...”

[srichardson8] 30/4/2021 17:51

The Board of EKF Diagnostics Holdings plc (AIM: EKF) has been informed that on 30 April 2021 Adam Reynolds, Non-Executive Director, sold a total of 500,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 73.05 pence per Ordinary Share.

[tongosti] 30/4/2021 17:32

The latest RNS tells us a company director sold 500k shares. He must have skipped your daily promotional posts. Do you mind emailing him on the value you (and a few others on here) place on Trellus? Lol.

[wan] 30/4/2021 09:23

Of note -

Amazon reaps rewards of pandemic shift online
Another quarter of $100bn-plus revenues sends shares to record high

Speaking on a call with journalists, Brian Olsavsky, chief financial officer, said ecommerce delivery speeds in Europe were now back to pre-pandemic levels, but that the US was “not quite” at full power. He said the company expected continued heavy investment in logistics in 2021, having added more than 500,000 workers in 2020.

Amazon said it expected net income to come in between $4.5bn and $8bn in the current quarter, factoring in $1.5bn in spending related to Covid-19 measures in its logistics network.

Full story -

Background -

Amazon’s B2B telehealth strategy and healthcare's future

David Bardan, Vice President and Head of Commercial at TytoCare tells us what Amazon’s B2B telehealth strategy means for the future of healthcare.

Leila Hawkins
Apr 26

Amazon is expanding its telehealth services to its employees in the US, with plans to offer the service to other companies as a workplace benefit for their own staff. Despite the rapid adoption of telehealth due to COVID-19, and the organisation having a vast network of consumers at its fingertips, the tech giant is choosing to expand its telehealth services through B2B partnerships rather than out to its customers.

Amazon has long been leading the way in streamlining access to products and services, and now that the company is turning its attention to healthcare, Bardan believes this will trigger further change across the industry. "By making high-quality care easy to access from the comfort of home, enabling immediate-term relief, peace of mind, and longitudinal wellness, Amazon is joining the ranks of telehealth companies like TytoCare that have been spearheading this shift."

This means companies that haven't yet invested in high-quality virtual care options risk lagging behind. However Bardan says telehealth adoption will continue to increase over the next few years. "In 2020, there was a huge shift in telehealth adoption, prompting multiple types of healthcare players to think more concretely about their strategy and invest in their virtual care infrastructure.

"In 2021 and beyond, we’ll start to see the pay offs from these investments, including higher quality visits, better clinical and diagnostic tools, and more continuity between virtual and in-person care. We’ll see this trend reinforce itself, in which quality spurs further adoption, spurring further investment. The telehealth technology is here, and consumers have demonstrated their willingness to use it."

Full story -

It would appear, according to my research (including 'elements' of my previous PBS posts), that EKF's PBS opportunity could ultimately be even larger than the MTM opportunity, especially as I see that opportunity extending beyond COVID-19 and potentially beyond PCR testing.

Manufacturing and offering MTM, ATM? and PBS, combined covers a very wide range of diagnostics and logistics opportunities!

[investorsat] 29/4/2021 14:42

Hi all

If you are approached by someone offering to buy your EKF shares at a considerable premium to the market price, please do not engage with them, they are operating an advance fee fraud, where you will be asked to make a payment up front in order to make the transaction happen. If you *do* make such a payment, they will just come back for more.

We have heard reports of EKF shareholders being targeted.

[wan] 29/4/2021 09:02

Is this the pull-back those waiting in the wings are waiting for?

Given the prospects, EKF must surely fit the buy on weakness rationale (we already know that Justin Urquhart Stewart has EKF in his sights), it will thus be very interesting to see what happens in the fullness of time.

[wanttowin] 28/4/2021 11:44

Added a few at 76.1p, I see no reason for the weakness.

[wan] 28/4/2021 09:34

Apologies in advance for the overload of information.

It's also worth understanding/estimating potential new products/markets, in this regard I have my eye on Stepan, a new account win for EKF.

Again, Hastings also covered this in his article (excerpt follows) -

And within this, another area worth touching upon was the more recent win with Illinois based Stepan, a two billion dollar turnover company that produces disinfectant for the healthcare market.

The CEO commented, “this contract worth $750k relating to Q3 is where we provide the raw material and the opportunity here for us could be very, very large”.

Baines also adds that the process to achieve scale is quite involved and takes time to achieve, but being conservative and rightly so, he is nevertheless looking at what appear attractive revenue numbers from two areas in relation to this for starters

That sees him anticipating figures of $3m to $4m per annum from both, as a minimum over the next two to three years where after achieving a scaling up, he says that you are then looking at high margin and high revenue.
(END)

Recently Stepan reported (27th April) a business priority was to -
Enable a healthier world through the supply of surfactants for cleaning, disinfection and personal wash applications.

Page 9 -

In another recent investor presentation (Mar 08, 2021) -

Key Market Needs and Stepan’s Solutions Page 10 -
Cleaning & Disinfection
Market Size:$45+Bn

Personal Hygiene
Market Size:$77+Bn


I am also content with Julian (CEO) being conservative (for the time being).

[wan] 28/4/2021 09:03

To perhaps better frame the above article in terms of how that might present opportunity to EKF, recently I stated the following -

During the recent Presentation meeting, Julian Baines (CEO) described EKF as supplying the picks & shovels to the Covid opportunity and described it as making the 'real' money. I also took note of him saying just after that comment, that EKF will/would/could (not sure which as I could not take notes quickly enough) become one of the world's major manufacturers of test kits.

I think he was also referring to the manufacture/assembly of home-use testing kits, and I assume such test kits being used beyond that of testing just the employees of the recently announced private sector partner (but again, those 1m + employees should not be underestimated, in terms of volumes, and perhaps not just for Coronavirus testing).
(END)

And Hastings also covered this aspect in his CEO interview/update (excerpt follows)-

He adds that the world was already going down that route before the onset of Covid and that has now accelerated, where given that this customer has such a huge distribution network and its own PCR lab it seems a natural progression for it move into home diagnostics.

Going on the CEO adds that EKF has been more than just a manufacturing partner as it has supported the customer through the tough regulatory hurdles as they have progressed.

“We had the expertise in this area to support and assist them and as a result we have become a very close- knit partner.
But, they haven’t invested millions in their own PCR lab to just stop when Covid quietens down, they are fully intended to move into other areas”.

Beyond this significant customer and the undoubted opportunities for EKF, I touch upon its wider position across manufacturing test kits.

The CEO says “there are a number of opportunities in front of us as companies have discovered that there are very few partners that can actually do the kitting”.

There are, he says, regulatory issues and quality that others cannot overcome which puts EKF in a very strong position for further progress across this area.
“In PrimeStore I see a huge opportunity as you have got to remember that it kills the pathogen, so I can see it being used in areas such as malaria or ebola and others.
As one example Public Health England have already got it in their workflow for pathogens not just Covid, so we see some really good opportunities ahead”.
Martins full article - hxxps://martinflitton1.wixsite.com/privatepunter/post/ekf-a-healthy-investment-09-03-21